Meet Dr. Raksha Jain
Cystic Fibrosis Specialist

Holder of the:
Dedman Family Scholar in Clinical Care

As Director of UT Southwestern Medical Center's Adult Cystic Fibrosis Program, pulmonologist Raksha Jain, M.D., is dedicated to providing – and developing – the most effective treatment plan for her patients.

We offer many exciting new therapies to cystic fibrosis patients."

Thanks to recent advancements such as gene mutation targeted therapies, she can offer more options than ever to help cystic fibrosis (CF) patients overcome issues such as malnutrition and recurrent respiratory infections.

Dr. Jain sees her patients on a regular basis and manages their CF care in the clinic and in the hospital.

"We don't just take care of their lungs,” Dr. Jain says. “We take care of their sinuses, their pancreatic and digestive problems, and their diabetes with help from our multi-disciplinary CF team."

It creates a strong bond that extends beyond a typical doctor-patient relationship. "We meet their families, and we know where they go to school and who they are married to," Dr. Jain says. "We really grow to know and care about our patients tremendously."

By choosing Dr. Jain and UT Southwestern for their care, CF patients benefit from a large center that has the resources to provide the best treatments, including lung transplantation. The lung transplant program at UT Southwestern has ranked in the top 10 in the United States for many years.

UT Southwestern is accredited by the Cystic Fibrosis Foundation, a designation that means Dr. Jain and her team meet the highest standards of care.

Dr. Jain is also active in clinical and molecular scientific research to help improve future care for patients with CF. Dr. Jain is co-principal investigator on the Cystic Fibrosis Foundation Therapeutics Development Network grant, which helps provide the infrastructure for conducting clinical trials to evaluate the safety and effectiveness of new CF therapies.

Her efforts to bring cystic fibrosis clinical trials to UT Southwestern mean that patients have easier access to the latest potential treatments – an option that they may have had to travel long distances for in the past.


  • Cystic fibrosis (CF) 
  • Bronchiectasis syndromes resembling cystic fibrosis
  • Pre and post-lung transplant cystic fibrosis